Travere Therapeutics Completes Sale of Bile Acid Product Portfolio to Mirum Pharmaceuticals • Travere received $210 million at closing and is eligible for up to $235 million in potential sales-based milestone payments• Mirum has acquired Travere’s rights and assets related to Cholbam® and...